

Mycofoli 250

Mycophenolate Mofetil I.P. 250 mg



Potent **immunosuppressive** action by selectively inhibiting lymphocyte proliferation.



Effective in preventing acute **organ rejection** in transplant patients.



Supports long-term **graft survival** and improves patient outcomes.



Well-tolerated with a favorable safety profile for chronic use.



Reduces risk of rejection in **kidney, heart** and **liver** transplantation.



Works at the **molecular level** to suppress immune overactivity.



Indications



Kidney Transplant



Liver Transplant



Heart Transplant



Autoimmune Disorders



Steroid-sparing Immunosuppression

References:

- Bullingham RE, Nicholls AJ. Mycophenolate mofetil: a review of its use in organ transplantation. *Drugs*. 2001;61(6):753-784.
- Allison AC. Mechanisms of action of mycophenolate mofetil. *Lupus*. 2005;14(Suppl 1):s2-s8.
- Vincenti F, et al. A pooled analysis of acute rejection episodes across studies of mycophenolate mofetil. *Transplantation*. 2003;76(5):696-701.
- Keown PA. Mycophenolate mofetil: an overview of its use in the prevention of organ transplant rejection. *Drugs*. 1999;58(2):219-245.